Startup Vima Adds Parkinson’s to Movement Disorder Scope, Expanding Series A Round to $100M

Vima Therapeutics is expanding to Parkinson’s disease following early clinical results showed proof of concept for its drug in isolated dystonia, a rare neurological movement disorder. The startup says its drug could address the biology underpinning many movement disorders. The post Startup Vima Adds Parkinson’s to Movement Disorder Scope, Expanding Series A Round to $100M…

Read More

Key Facts About Medicare Drug Price Negotiation

Under the Medicare Drug Price Negotiation Program, the federal government negotiates prices with drug companies for certain high-cost drugs covered under Medicare Part B and Part D. This brief provides information about several key aspects of the Medicare drug price negotiation program, with a focus on the 2028 implementation year.

Read More

Michael Dalton, Ovatient

Michael Dalton is CEO of Ovatient — it’s a telehealth company built on Epic that comes out of health systems (Medical University of South Carolina and Metro Health, Cleveland, OH). It does the integration and care continuity between its medical group and health systems (a little like KeyCare which also serves health system). I asked…

Read More

Cosmetic Surgery Investigation Prompts Warnings for Patients, and a Push for Tighter Safety Standards

An investigation into cosmetic surgery chains by KFF Health News and NBC News has prompted consumer warnings from industry groups representing plastic surgeons and a call for more transparency around physician disciplinary actions in California. The American Society of Plastic Surgeons, which represents 12,000 doctors, is now warning patients to “do their homework” before getting…

Read More

Payers and targeted therapy in oncology

I was quoted in a recent article in Pharmaceutical Technology titled “Targeted therapies to join chemo as oncology treatment backbone“. An excerpt is below: Though payers could theoretically prioritise chemotherapy over the use of targeted treatments due to their lower price, Jason Shafrin, senior managing director of FTI’s Center for Healthcare Economics and Policy, notes…

Read More